All In Biotech

Drug Trial Radar · NCT05398679

Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis

Last checked: Nov 19, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 360 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

360

Planned (sponsor's estimate)

Start

Aug 17, 2022

Primary completion

Dec 30, 2026

Study completion Dec 30, 2027

Sponsor

Lead sponsor
Fundacion Clinic per a la Recerca BiomédicaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 1, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Non-inferiority trial to determine whether partial oral treatment is non-inferior to OPAT(Outpatient parenteral therapy) in patients diagnosed with infective endocarditis

Conditions

  • Endocarditis Infective

Interventions

  • CefaclorDrug

    cefaclor intravenous 2 gr/day

  • Ciprofloxacin TabletsDrug

    500-750 mg/12 hrs (maximum 3g x day)

  • Ciprofloxacin InjectionDrug

    1200 mg/day maximum dose IV

  • Clindamycin Oral CapsuleDrug

    600 mg/8 hours (maximum 1.800 mg x day)

  • Clindamycin InjectionDrug

    600 mg/8 hours (maximum 1.800 mg x day) IV

  • Dicloxacillin Oral CapsuleDrug

    1g/8 hours (maximum 4 gr day)

  • DicloxacillinDrug

    1g/8 hours (maximum 4 g x day) IV

  • Fusidic Acid Only Product in Oral Dose FormDrug

    0,750g/12 hours (maximum 1,5 g x day)

  • Fusidic Acid Only Product in Parenteral Dose FormDrug

    0,75 g/12 hours (maximum 1,5 g x day)

  • Levofloxacin Oral TabletDrug

    0.5g/12-24hours (maximum 1 g x day)

  • Levofloxacin InjectionDrug

    0.5g/12-24hours (maximum 1 g x day)

  • Linezolid Oral TabletDrug

    0,6 g/12 hours (maximum 1200 mg x day)

  • Linezolid Injectable ProductDrug

    0,6 g/12 hours (maximum 1200 mg x day)

  • Moxifloxacin tabletDrug

    0,4 g/day (maximum 400 mg x day)

  • Moxifloxacin Injectable ProductDrug

    0,4 g/day (maximum 400 mg x day)

  • Rifampicin Only Product in Oral Dose FormDrug

    0,3-0,5 g/12 hours (maximum 1200 mg x day)

  • Rifampicin Only Product in Parenteral Dose FormDrug

    0,3-0,6 g/12 hours (maximum 1200 mg x day)

  • Sulfamethoxazole / Trimethoprim Oral Tablet [Bactrim]Drug

    sulfamethoxazole 1600 mg/trimethoprin 320 mg (maximum x day)

  • Sulfamethoxazole / Trimethoprim Injectable ProductDrug

    sulfamethoxazole 1600 mg/trimethoprin 320 mg (maximum x day)

  • Tedizolid Oral TabletDrug

    200 mg tedizolid (maximum x day)

  • Tedizolid InjectionDrug

    200 mg (maximum x day)

  • Amoxicillin CapsulesDrug

    1 gr/6 hours (4 g x day)

  • AmoxicillinDrug

    1 gr/6 hours (4 g x day) Intravenous

  • Cefaclor CapsulesDrug

    2 gr/day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Non-inferiority of outpatient oral vs parenteral antibiotic therapy measured by the number of unplanned hospitalizationsTime frame: At any time during the study duration (up to 24 months)
  2. Non-inferiority of outpatient oral vs parenteral antibiotic therapy measured by the number of all-cause mortalityTime frame: At any time during the study duration (up to 24 months)
  3. Non-inferiority of outpatient oral vs parenteral antibiotic therapy measured by the number of relapses of Infective EndocarditisTime frame: within 6 months from diagnosis of Infective Endocarditis
  4. Non-inferiority of outpatient oral vs parenteral antibiotic therapy measured by the number of patients requiring cardiac surgeryTime frame: At any time during the study duration (up to 24 months)

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Hospital General de Alicante

    Alicante, Alicante, Spain · Recruiting

  • Hospital Virgen de la Macarena

    Seville, Andalusia, Spain · Recruiting

  • Hospital Virgen del Rocío

    Seville, Andalusia, Spain · Recruiting

  • Hospital Son Espases

    Palma de Mallorca, Balearic Islands, Spain · Recruiting

  • Hospital del Mar

    Barcelona, Barcelona, Spain · Recruiting

  • Hospital Clinic i Provincial de Barcelona

    Barcelona, Barcelona, Spain · Recruiting

  • Hospital Sant Pau

    Barcelona, Barcelona, Spain · Recruiting

  • Hospital Bellvitge

    Barcelona, Barcelona, Spain · Recruiting

  • Parc Taulí Hospital Universitari

    Sabadell, Barcelona, Spain · Recruiting

  • Hospital Mútua de Terrassa

    Terrassa, Barcelona, Spain · Recruiting

  • Hospital Universitario de Cruces

    Barakaldo, Bizcaia, Spain · Recruiting

  • Hospital Universitario Marqués de Valdecilla

    Santander, Cantabria, Spain · Recruiting

  • Hospital Universitario de Donostia

    Donostia / San Sebastian, Guipuzcoa, Spain · Recruiting

  • Hospital San Pedro

    Logroño, La Rioja, Spain · Recruiting

  • Hospital General Universitario Gregorio Marañón

    Madrid, Madrid, Spain · Recruiting

  • Hospital Ramón y Cajal

    Madrid, Madrid, Spain · Recruiting

  • Hospital Universitario La Paz

    Madrid, Madrid, Spain · Recruiting

  • Hospital Virgen de Arrixaca

    El Palmar, Murcia, Spain · Recruiting

  • Hospital universitario de Canarias

    San Cristóbal de La Laguna, Santa Cruz de Tenerife, Spain · Recruiting

  • Hospital Universitari i Politècnic La Fe

    Valencia, València, Spain · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.